IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (1536)	4/12/1998 1:21:00 AM
From: Maurice Winn	Read Replies (1) of 1762

Richard, That was a quintuple negative - Guiness material. Count them! "It isn't[1] that I don't[2] think CD20 MAbs won't[3] be ineffective[4], its just that I'm unsure[5] that they will. So it seems from the trials you mention that Rituxan is indeed expected to give good results in NHLs of the intermediate and high grade type if strongly CD20. Which is what I thought originally. The only objection I've heard is that tuberculosis [and presumbably other infections are a risk]. It seems to me that P53 testing should be done and if the alleles, 7 through 9 [I think they were] are mutant, then Rituxan should be essential treatment because those patients have rotten prospects according to the Blood Nov 97. report. Going to try for a sextuplet negative? Regards, Maurice

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next